Drug repositioning is a method used to discover the novel uses of approved drugs through the PPI network.[42] Shahjaman et al predicted 16 small-molecule drugs for the treatment of ovarian cancer by constructing a PPI network of DEGs.[43] Wang et al identified 15 drugs suitable for treating melanoma by constructing a PPI network of hub genes in the co-expression network.[44] Based on the PPI network of CCL23 and HNF1B, we identified that artenimol and pascolizumab may be appropriate for the treatment of patients with LUSC. This evidence concerns the gene HNF1B and ovarian cancer.